These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31755139)

  • 1. Ruxolitinib for steroid-refractory acute graft-versus-host disease.
    Toama W; Fiala M; Pusic I; Westervelt P; Dipersio JF; Schroeder M
    Transpl Int; 2020 Feb; 33(2):244-246. PubMed ID: 31755139
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results.
    González Vicent M; Molina B; González de Pablo J; Castillo A; Díaz MÁ
    Am J Hematol; 2019 Mar; 94(3):319-326. PubMed ID: 30536806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
    Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
    JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond ruxolitinib in steroid-refractory acute graft-versus-host disease.
    Lee CJ; Pusic I; Savani BN
    Br J Haematol; 2021 Nov; 195(3):306-307. PubMed ID: 34402041
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-vs-Host Disease-Another Hopeful Step Forward.
    Alvarnas JC
    JAMA Netw Open; 2021 Jan; 4(1):e2035719. PubMed ID: 33502479
    [No Abstract]   [Full Text] [Related]  

  • 10. Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients.
    Khandelwal P; Teusink-Cross A; Davies SM; Nelson AS; Dandoy CE; El-Bietar J; Marsh RA; Kumar AR; Grimley MS; Jodele S; Myers KC
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1122-1127. PubMed ID: 28344057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
    Przepiorka D; Luo L; Subramaniam S; Qiu J; Gudi R; Cunningham LC; Nie L; Leong R; Ma L; Sheth C; Deisseroth A; Goldberg KB; Blumenthal GM; Pazdur R
    Oncologist; 2020 Feb; 25(2):e328-e334. PubMed ID: 32043777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
    Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
    Belina ME; Driscoll TA; Blanchard SK; Cardones AR
    Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
    J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
    Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory/dependent acute, gastrointestinal graft-versus-host disease: A case series.
    Biliński J; Jasiński M; Tomaszewska A; Lis K; Kacprzyk P; Chmielewska L; Karakulska-Prystupiuk E; Mullish BH; Basak GW
    Am J Hematol; 2021 Dec; 96(12):E461-E463. PubMed ID: 34587331
    [No Abstract]   [Full Text] [Related]  

  • 17. Ruxolitinib for steroid-resistant acute GVHD.
    Risitano AM; Peffault de Latour R
    Blood; 2020 May; 135(20):1721-1722. PubMed ID: 32407526
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults.
    Moiseev IS; Morozova EV; Bykova TA; Paina OV; Smirnova AG; Dotsenko AA; Borzenkova ES; Galimov AN; Gudognikova YV; Ekushov KA; Kozhokar PV; Osipova AA; Pirogova OV; Rudakova TA; Klimova OU; Tcvetkov NY; Kulagin EA; Surkova EA; Lapin SV; Rodionov GG; Moiseev SI; Serov YA; Zubarovskaya LS; Afanasyev BV
    Bone Marrow Transplant; 2020 Jul; 55(7):1379-1387. PubMed ID: 32071418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level.
    Modemann F; Ayuk F; Wolschke C; Christopeit M; Janson D; von Pein UM; Kröger N
    Bone Marrow Transplant; 2020 Dec; 55(12):2286-2293. PubMed ID: 32447349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
    Escamilla Gómez V; García-Gutiérrez V; López Corral L; García Cadenas I; Pérez Martínez A; Márquez Malaver FJ; Caballero-Velázquez T; González Sierra PA; Viguria Alegría MC; Parra Salinas IM; Calderón Cabrera C; González Vicent M; Rodríguez Torres N; Parody Porras R; Ferra Coll C; Orti G; Valcárcel Ferreiras D; De la Cámara LLanzá R; Molés P; Velázquez-Kennedy K; João Mende M; Caballero Barrigón D; Pérez E; Martino Bofarull R; Saavedra Gerosa S; Sierra J; Poch M; Zudaire Ripa MT; Díaz Pérez MA; Molina Angulo B; Sánchez Ortega I; Sanz Caballer J; Montoro Gómez J; Espigado Tocino I; Pérez-Simón JA;
    Bone Marrow Transplant; 2020 Mar; 55(3):641-648. PubMed ID: 31700138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.